14 January 2022 in ACS Nano
10 January 2022 in Journal of Clinical Oncology
PURPOSE: Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain.PATIENTS AND METHODS: We performed targeted error-corrected sequencing on samples from 1,727 donors age 40 years or older and assessed the effect of donor CH on recipient clinical outcomes. We measured long-term engraftment of 102 donor clones and cytokine levels in 256 recipients at 3 and 12 months after transplant.RESULTS: CH was present in 22.5% of donors, with DNMT3A (14.6%) and TET2 (5.2%) mutations being most common; 85% of donor clones showed long-term engraftment in recipients after transplantation, including clones with a variant allele fraction < 0.01. DNMT3A-CH with a variant allele fraction ≥ 0.01, but not smaller clones, was associated with improved recipient overall (hazard ratio [HR], 0.79; P = .042) and progression-free survival (HR, 0.72; P = .003) after adjustment for significant clinical variables. In patients who received calcineurin-based graft-versus-host disease prophylaxis, donor DNMT3A-CH was associated with reduced relapse (subdistribution HR, 0.59; P = .014), increased chronic graft-versus-host disease (subdistribution HR, 1.36; P = .042), and higher interleukin-12p70 levels in recipients. No recipient of sole DNMT3A or TET2-CH developed donor cell leukemia (DCL). In seven of eight cases, DCL evolved from donor CH with rare TP53 or splicing factor mutations or from donors carrying germline DDX41 mutations.CONCLUSION: Donor CH is closely associated with clinical outcomes in transplant recipients, with differential impact on graft alloimmune function and potential for leukemic transformation related to mutated gene and somatic clonal abundance. Donor DNMT3A-CH is associated with improved recipient survival because of reduced relapse risk and with an augmented network of inflammatory cytokines in recipients. Risk of DCL in allogeneic hematopoietic cell transplantation is driven by somatic myelodysplastic syndrome–associated mutations or germline predisposition in donors.
14 August 2019 in PLOS ONE
We describe a new genome alignment-based model for understanding the diversity of viruses based on evolutionary genetic relationships. This approach uses information theory and a physical model to determine the information shared by the genes in two genomes. Pairwise comparisons of genes from the viruses are created from alignments using NCBI BLAST, and their match scores are combined to produce a metric between genomes, which is in turn used to determine a global classification using the 5,817 viruses on RefSeq. In cases where there is no measurable alignment between any genes, the method falls back to a coarser measure of genome relationship: the mutual information of 4-mer frequency. This results in a principled model which depends only on the genome sequence, which captures many interesting relationships between viral families, and which creates clusters which correlate well with both the Baltimore and ICTV classifications. The incremental computational cost of classifying a novel virus is low and therefore newly discovered viruses can be quickly identified and classified. The model goes beyond alignment-free classifications by producing a full phylogeny similar to those constructed by virologists using qualitative features, while relying only on objective genes. These results bolster the case for mathematical models in microbiology which can characterize organisms using only their genetic material and provide an independent check for phylogenies constructed by humans, considerably faster and more cheaply than less modern approaches.
10 March 2026 in Communications Medicine
Background: Tuberculosis (TB) is one of the leading causes of death worldwide, even though it is curable using antibiotics. Most people who die of TB never begin treatment because diagnostics are insufficiently sensitive and accessible. We aimed to measure low-abundance biomarkers and diagnose TB in urine. Methods: We developed and clinically validated a multiplex Single Molecule Array (Simoa) assay to detect TB in urine by measuring two TB biomarkers: lipoarabinomannan (LAM) and antigen 85B (Ag85B). Using antibodies that recognize different epitopes of LAM in a four-plex assay with three LAM and one Ag85B antibody pairs, we trained a model and demonstrated its performance in retrospective cohorts totaling 576 individuals from South Africa, Peru, Vietnam, and Cambodia, including a blinded test cohort ( n = 215). Results: Here we present an assay that classifies samples with 98% specificity, 45% sensitivity overall, and 58% sensitivity among people living with the human immunodeficiency virus (HIV). Conclusions: Different antibody pairs detecting different epitopes on LAM report diverging concentrations. We do not find that adding antibody pairs to detect different epitopes on LAM improves the assay’s accuracy. Our assay is more sensitive than the existing AlereLAM lateral flow test for TB in HIV-positive individuals, uses safe and accessible urine samples, and represents a step towards an adjunctive diagnostic test to aid clinicians in starting treatment.